Call Options

3 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q4 2023

Feb 14, 2024

SELL
$338.91 - $506.01 $10.3 Million - $15.3 Million
-30,300 Reduced 59.18%
20,900 $7.95 Million
Q3 2023

Nov 14, 2023

BUY
$369.35 - $548.43 $16.1 Million - $23.9 Million
43,600 Added 573.68%
51,200 $25.2 Million
Q2 2023

Aug 14, 2023

BUY
$360.14 - $422.58 $2.74 Million - $3.21 Million
7,600 New
7,600 $2.96 Million

Others Institutions Holding ARGX

About ARGENX SE


  • Ticker ARGX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 55,323,800
  • Market Cap $31.2B
  • Description
  • argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...
More about ARGX
Track This Portfolio

Track Boothbay Fund Management, LLC Portfolio

Follow Boothbay Fund Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Boothbay Fund Management, LLC with notifications on news.